Serum miR-181a and miR-25 in patients with malignant and benign breast diseases-Reference-Cited by-同舟云学术

Serum miR-181a and miR-25 in patients with malignant and benign breast diseases

Published:2023 Issue:5 Volume:69 Page:307-314
ISSN:2310-6905
Container-title:Biomeditsinskaya Khimiya
language:ru
Short-container-title:BIOMED KHIM

Author:

Perepechaeva M.L.¹,Studenikina A.A.¹,Grishanova A.Yu.²,Glushkov A.N.³,Polenok E.G.³,Bajramov P.V.⁴,Autenshlyus A.I.¹

Affiliation:

1. Novosibirsk State Medical University, Novosibirsk, Russia; Research Institute of Molecular Biology and Biophysics, Federal Research Center for Fundamental and Translational Medicine, Novosibirsk, Russia

2. Research Institute of Molecular Biology and Biophysics, Federal Research Center for Fundamental and Translational Medicine, Novosibirsk, Russia

3. Institute of Human Ecology of the Federal Research Center of Coal and Coal Chemistry SB RAS, Kemerovo, Russia

4. M.S. Rappoport Kuzbass Clinical Oncologic Dispensary, Kemerovo, Russia

Abstract

Breast tumor diseases include a wide range of pathologies that require different approaches to their treatment. MicroRNA (miR) levels, reflecting regulation of the gene expression involved in tumorigenesis, can be diagnostic and prognostic markers of breast diseases. The levels of circulating miR-181a and miR-25 were measured in patients with benign breast diseases (BBD), patients with invasive carcinoma of a nonspecific type (ICNT) and also in conditionally healthy women. Expression of both miRs was higher in patients of both groups as compared to controls; at the same time, the content of serum miR-181a and miR-25 was higher in BBD patients than in ICNT patients. The detected changes may be of interest in the context of precancerous changes in BBD. It seems possible to use them in the future as markers of the pathological process as a part of a large diagnostic panel.

Publisher

Institute of Biochemistry

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference27 articles.

1. Łukasiewicz S., Czeczelewski M., Forma A., Baj J., Sitarz R., Stanisіawek A. (2021) Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies – an updated review. Cancers, 13(17), 4287.

2. Breast Tumours (2019) International agency for besearch on cancer: Lyon, 298 p.

3. Zhai Z., Mu T., Zhao L., Li Y., Zhu D., Pan Y. (2022) miR-181a-5p facilitates proliferation, invasion, and glycolysis of breast cancer through NDRG2-mediated activation of PTEN/AKT pathway. Bioengineered, 13(1), 83-95.

4. Yang C., Tabatabaei S.N., Ruan X., Hardy P. (2017) The dual regulatory role of mir-181a in breast cancer. Cell. Physiol. Biochem., 44(3), 843-856.

5. Mahmoudian M., Razmara E., Mahmud Hussen B., Simiyari M., Lotfizadeh N., Motaghed H., Khazraei Monfared A., Montazeri M., Babashah S. (2021) Identification of a six-microRNA signature as a potential diagnostic biomarker in breast cancer tissues. J. Clin. Lab. Anal., 35(11), e24010.